Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors

Annals of the New York Academy of Sciences

Volumn 886, Issue , 1999, Pages 58-66

  Iruela Arispe, M Luisa ^a   Vázquez, Francisca ^a   Ortega, Maria Asunción ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COMPLEMENTARY DNA; DISINTEGRIN; METALLOPROTEINASE; METALLOSPONDIN; SCLEROPROTEIN; THROMBOSPONDIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER GROWTH; CAPILLARY; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; MAMMARY GLAND; MOLECULAR CLONING; MOUSE MAMMARY TUMOR ONCOVIRUS; NEOVASCULARIZATION (PATHOLOGY); PROMOTER REGION; PROTEIN FAMILY; TUMOR VOLUME;

ANIMALIA; MAMMARY TUMOR ONCOVIRUS; MOUSE MAMMARY TUMOR VIRUS; ONCOVIRINAE;

EID: 0033452546     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09400.x     Document Type: Conference Paper

References (57)

1. 1. Sanger, R. 1989. Tumor suppressor genes: The puzzle and the promise. Science 246: 1406-1412.
2. 2. Bishop, J.M. 1987. The molecular genetics of cancer. Science 235: 305-311.
3. 3. Harris, H. 1986. The genetic analysis of malignancy. J. Cell Sci. Suppl. 4: 431-444.
4. 4. Weinberg, R.A. 1988. Finding the anti-oncogene. Sci. Am. 259: 34-41.
5. 5. Folkman, J. 1990. What is the evidence that tumors are angiogenic-dependent? J. Natl. Cancer Inst. 82: 4-6.
6. 6. Folkman, J. 1996. New perspectives in clinical oncology from angiogenesis research. Eur. J. Cancer 32: 2534-2539.
7. 7. Blood, C.H. & B.R. Zetter. 1990. Tumor interactions with the vasculature: Angiogenesis and tumor metastasis. Biochim. Biophys. Acta 1032: 89-118.
8. 8. Weidner, N. 1992. The relationship of tumor angiogenesis and metastasis with emphasis on invasive breast carcinoma. In Advances in Pathology.: 101-122. Chicago.
9. 9. Weidner, N. et al. 1992. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 84: 1875-1887.
10. 10. Weidner, N. et al. 1991. Tumor angiogenesis and metastasis: Correlation in invasive breast carcinoma. N. Engl. J. Med. 324: 1-8.
11. 11. Bosari, S. et al. 1992. Microvessel quantitation and prognosis in invasive breast carcinoma. Human Pathol. 23: 755-761.
12. 12. Folkman, J. et al. 1963. Growth and metastasis of tumor in organ culture. Cancer 16: 453-467.
13. 13. Barnhill, R.L. & M.A. Levy. 1993. Regressing thin cutaneous malignant melanomas (< 1.0 mm) are associated with angiogenesis. Am. J. Pathol. 143: 99-104.
14. 14. Brem, S.S. et al. 1990. Inhibition of angiogenesis and tumor growth in the brain. Am. J. Pathol. 137: 1121-1142.
15. 15. Langer, R. et al. 1976. Isolation of a cartilage factor that inhibits tumor neovascularization. Science 193: 70-72.
16. 16. Langer, R.S. et al. 1980. Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc. Natl. Acad. Sci. USA 77: 4431-4335.
17. 17. Takigawa, M. et al. 1985. A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B 16 melanomas: Its relation with cartilage-derived anti-tumor factor (CATF). Biochem. Int. 14: 357-363.
18. 18. Moses, M.A. et al. 1990. Identification of an inhibitor of neovascularization from cartilage. Science 248: 1408-1410.
19. 19. Peterson, H.I. 1986. Tumor angiogenesis inhibition by prostaglandin synthetasc inhibitors. Anticancer Res. 6: 251-254.
20. 20. Taylor, S. & J. Folkman. 1982. Protamine is an inhibitor of angiogenesis. Nature 297: 307-312.
21. 21. Ingber, D. et al. 1990. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555-558.
22. 22. Ferrara, N. 1995. The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res. Treat. 36: 127-137.
23. 23. Brooks, P.C. et al. 1995. Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96: 1815-1822.
24. 24. O'Reilly, M.S. et al. 1994. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328.
25. 25. O'Reilly, M.S. et al. 1997. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285.
26. 26. Rastinejad, F. et al. 1989. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 56: 345-355.
27. 27. Good, D.J. et al. 1990. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc. Natl. Acad. Sci. USA 87: 6624-6628.
28. 28. Iruela-Arispe, M.L et al. 1991. Thrombospondin exerts an antiangiogenic effect on tube formation by endothelial cells in vitro. Proc. Natl. Acad. Sci. USA 88: 5026-5030.
29. 29. Iruela-Arispe, M.L et al. 1996. Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in human stromal cells. J. Clin. Invest. 97: 403-412.
30. 30. Iruela-Arispe, M.L et al. 1999. Inhibition of angiogenesis by thrombospondin-1 is mediated by two independent regions within the type I repeats. Circulation. In press.
31. 31. Guo, N.H. et al. 1997. Antiproliferative and antitumor activities of D-reverse peptides derived from the second type I repeats of thrombospondin. Structural requirements for hcparin binding and promotion of melanoma cell adhesion and chemotaxis. J. Pept. Res. 50: 210-221.
32. 32. Tolsma, S.S. et al. 1993. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J. Cell Biol. 122: 497-511.
33. 33. Vasquez, F. 1999. METH 1 and METH 2, members of a new family of proteins with angio-inhibitory domains. J. Biol. Chem. In press.
34. 34. Colige, A. et al. 1997. cDNA cloning and expression of bovine procollagen I N-proteinase: A new member of the superfamily of zinc-metalloproteinases with binding sites for cells and other matrix components. Proc. Natl. Acad. Sci. USA 94: 2374-2379.
35. 35. Kuno, K. et al. 1997. Molecular cloning of a gene encoding a new type of metallo-proteinase-disinfegrin family protein with thrombospondin motifs as an inflammation associated gene. J. Biol. Chem. 272: 556-562.
36. 36. Guo, N.H. et al. 1992. Heparin-and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. Proc. Natl. Acad. Sci. USA 89: 3040-3044.
37. 37. Guo, N.H. et al. 1992. Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J. Biol. Chem. 267: 19349-19355.
38. 38. Schultz-Cherry, S. et al. 1995. Regulation of transforming growth factor ß activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270: 7304-7310.
39. 39. Klar, A. et al. 1992. F-spondin, a gene expressed at high levels in the floor plate encodes a secreted protein that promotes neural cell adhesion and neurite extension. Cell 69: 95-103.
40. 40. Leung-Hagesteijn, C. et al. 1992. Unc-5, a transmembrane protein with immuno-globulin and thrombospondin type I domains, guides cell and pioneer axon migrations in Caenorhabditis elegans. Cell 71: 289-299.
41. 41. Simmons, D.L. et al. 1989. Identification of a phorbol ester-repressible v-src inducible gene. Proc. Natl. Acad. Sci. USA 86: 1178-1187.
42. 42. O'Brien, T.P. et al. 1990. Expression cyr61, a growth factor-inducible immediate-early gene. Mol. Cell Biol. 10: 3569-3576.
43. 43. Ryseck, R.-P. et al. 1991. Structure, mapping, and expression of fisp-12, a growth factor-inducible gene encoding a secreted cysteine rich protein. Cell Growth Differ. 2: 225-232.
44. 44. Bradham, D.M. et al. 1991. Connective tissue growth factor: A cysteine-rich mitogen secreted by vascular endothelial cells is related to the .src-induced immediate early gene product CHF-10. J. Cell. Biol. 114: 1285-1294.
45. 45. Joliot, V. et al. 1992. Proviral rearrangements and overexprcssion of a new cellular gene (nov) in myelohlastosis-associated virus type 1-induced nephroblastomas. Mol. Cell. Biol. 12: 10-19.
46. 46. Brunner, A. et al. 1991. Identification of a gene family regulated by transforming growth factor ß. DNA Cell Biol. 10: 293-305.
47. 47. Ozaki, L.S. et al. 1983. Structure of the Plasmodium knowlesi gene coding for the circumsporozoite protein. Cell 34: 815-821.
48. 48. Robson, K.J.H. et al. 1988. A highly conserved amino acid sequence in thrombospondin, properdin, and in proteins from sporozoites and blood stages of a human malaria parasite. Nature 335: 79-86.
49. 49. Cerami, C. et al. 1992. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein Plasmodium falciparum sporozoites. Cell 70: 1021-1032.
50. 50. Holt, G.D. et al. 1990. Properdin binds to sulfatidc (Gal(3-SO4)ß1-1Cer) and has a sequence homology with other proteins that binds sulfated glycoconjugates. J. Biol. Chem. 265: 2852-2863.
51. 51. Prater, C.A. et al. 1991. The properdin-like repeats of thrombospondin contain a cell attachment site. J. Cell Sci. 112: 1031-1039.
52. 52. PANCAKE, S.J. et al. 1992. Malaria sporozoites and circumsporozoite proteins bind specifically to sulfated glycoconjegates. J. Cell Biol. 117: 1351-1361.
53. 53. Frevert, U. et al. 1993. Malaria circumsporozoite proteins binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp. Med. 177: 1287-1291.
54. 54. Müller, H.-M. et al. 1993. Thrombospondin-related anonymous protein (TRAP) of Plasmodium falciparum binds specifically to sulfaled glycoconjugates and to HepG2 hepatoma cells suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 12: 2881-2893.
55. 55. Higgins, J.M.G. et al. 1995. Characterization of mutant forms of recombinant human properdin lacking single thrombsopondin type I repeats. J. Immunol. 155: 5777-5785.
56. 56. Boehm, T. et al. 1997. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 39: 404-407.
57. 57. Iruela-Arispe, M.L. & H. Dvorak. 1997. Angiogenesis: A dynamic balance of stimulator and inhibitors. Thromb. Haematol. 78: 672-677.